This morning,Ā AtaiBeckleyĀ shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD).
The open-label extension (OLE) saw participants offered a second, 12 mg dose of the short-acting psychedelic after the 8-week blinded period during which they received one of three first doses (0.3 mg, 8 mg, or 12 mg).
AtaiBeckley, which just last week adopted its present name after a merger betweenĀ atai Life SciencesĀ andĀ Beckley PsytechĀ closed, reports that the second dose āproduced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksā.
We reviewed the readout and spoke with AtaiBeckley CEO,Ā Srinivas Rao, to dive a little deeperā¦
Sign-in or join PĪ±+ to continue reading this article…
JoinĀ PĪ±+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
āĀ Ā Regular Bulletins covering key topics and trends in the psychedelics space
āĀ Ā Regular articles and deep dives across psychedelic research, policy and business
āĀ Ā Interviews with insiders
āĀ Ā Monthly interactive database and commentary on psychedelic patents
āĀ Ā Quick-take analysis of major developments
āĀ Ā A Library of primers and explainers
āĀ Ā Access to our full back catalogue
